Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. (original) (raw)
Research Article Free access | 10.1172/JCI117112
B Nag, S D Sharma, N Willcox, A Vincent, D J Ferguson, and J Newsom-Davis
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Find articles by Nicolle, M. in:[JCI](/search/results?q=author.first%5Fname%3A%22M W%22+author.last%5Fname%3A%22Nicolle%22&search%5Ftype=advanced) |PubMed |Google Scholar
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Find articles by Nag, B. in:JCI |PubMed |Google Scholar
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Find articles by Sharma, S. in:[JCI](/search/results?q=author.first%5Fname%3A%22S D%22+author.last%5Fname%3A%22Sharma%22&search%5Ftype=advanced) |PubMed |Google Scholar
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Find articles by Willcox, N. in:JCI |PubMed |Google Scholar
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Find articles by Vincent, A. in:JCI |PubMed |Google Scholar
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Find articles by Ferguson, D. in:[JCI](/search/results?q=author.first%5Fname%3A%22D J%22+author.last%5Fname%3A%22Ferguson%22&search%5Ftype=advanced) |PubMed |Google Scholar
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Find articles by Newsom-Davis, J. in:JCI |PubMed |Google Scholar
Published April 1, 1994 -More info
Published April 1, 1994 -Version history
In autoimmune disorders, inactivation of pathogenic antigen-specific T cells, rather than global immunosuppression, would be highly desirable. One way to achieve this would be to deliver the first antigen-specific signal to the T cell in the absence of the second costimulatory signal. Myasthenia gravis (MG) is a well-characterized autoimmune disease in which T cell-dependent autoantibodies are directed against the acetylcholine receptor (A ChR) at the neuromuscular junction. AChR-specific T cells have been cloned from MG patients, and in this study, we have induced long-lasting tolerance in vitro in one particular clone (PM-A1) with a known peptide epitope (alpha 144-163) and MHC class II restriction (DR4 Dw14.2 or 4.2) by using soluble MHC-class II peptide complexes. Preincubation of PM-A1 T cells with such complexes induced death by apoptosis in < or = 40-50% of the AChR-specific cells. Surviving cells remained refractory to stimulation with AChR-derived synthetic peptides or recombinant polypeptides for < or = 38 d after complex treatment. These effects were highly specific, dose-dependent and required > 2 h preincubation. The T cells could be protected from the tolerizing effects of complex by coincubation with DR-matched or -mismatched antigen-presenting cells. This work shows that antigen-specific T cells can be selectively killed or anergized using soluble MHC class II: peptide complexes. Such an antigen-specific therapy offers a rational approach to the immunotherapy of autoimmune or allergic disease in vivo.
Images.
Click on an image below to see the page. View PDF of the complete article
- Version 1 (April 1, 1994): No description